Business Wire

NTT-DATA

8.2.2024 09:01:34 CET | Business Wire | Press release

Share
NTT DATA Report Signals a Paradigm Shift as Banks Finally Migrate from Mainframes to AI-driven Cloud Technologies

NTT DATA, a global digital business and IT services leader, today announced a new global banking research report entitled "The Digital Horizon: Banking’s Shift from Mainframe to AI-Driven Cloud Infrastructure.” The research has unveiled findings from a survey of 650 global banking decision-makers, marking a definitive shift in the sector towards agile and customer-focused banking. Moreover, the survey uncovers a transformative trend: banks are finally pivoting from entrenched mainframe systems to adopt AI and cloud technologies, spurred by the multiple headwinds they face of consumer demands, innovative new market disruption, and the competitive pressures of innovative technological advancements.

Modernisation and Transformation Trends:

  • Enduring Mainframes: Despite 89% of banking leaders identifying as innovators, 63% still operate on mainframe systems, confirming the mainframe’s resilience.
  • Cloud Migration to Increase from Generative AI injection: 63% of banking decision-makers confirm generative AI is decisively facilitating the transition of banking applications to the cloud
  • Generative AI Gaining Board-Level Support: A resounding 91% report their AI and cloud initiatives are endorsed by the board, signalling strategic prioritisation.
  • Navigating Skill Gaps: With 80% lacking a strategic framework for generative AI adoption, the need for upskilling is evident.
  • 45% of banks are already integrating generative AI technology into their technology stacks while a further 30% are in the early stages of looking at it.
  • Cloud as an Innovation Enabler: Flexibility and scalability are cited by 36% of respondents as key drivers for cloud migration, indicating a shift beyond cost concerns.

The enduring stronghold of mainframes in the banking sector is poised for a significant shift, thanks to the integration of generative AI into cloud migration strategies. NTT DATA's research reveals that 63% of banking decision-makers confirm generative AI is decisively facilitating the transition of banking applications to the cloud, indicating a transformative phase where mainframes’ resilience meets the agility of cloud computing.

25% of respondents also acknowledge a growing trend in cloud migration, propelled by AI advancements. This heralds a new era where the collaboration between AI’s potential to reinterpret legacy code and cloud technology's scalability is accelerating modernisation and transformation initiatives, suggesting that the longstanding reign of mainframes is approaching its horizon.

Kaz Nishihata, Director and Senior Executive Vice President at NTT DATA Group Corporation, commented: "Banks are not only evolving technologically but also culturally. The industry’s rapid adoption of AI and cloud is redefining business models and establishing a new norm in sector leadership. This technological tide is propelling banks toward a more intimate understanding of customer needs, delivering services that are faster, more secure, and uniquely tailored."

The research also found that the banking industry is rapidly embracing the transformative power of generative AI, with 45% of banks already incorporating it into their operations. Additionally, 30% are exploring its potential, signalling a proactive shift towards innovation. This adoption underscores the sector's commitment to future-proofing services and the desire for organisations to enhance their competitive edge in a fast-evolving digital landscape.

Nishihata adds, “The momentum for generative AI across the banking sector is a testament to the industry’s resolve to move beyond traditional mainframes, leveraging cloud environments to fortify security, enhance robustness, innovate, and boldly redefine. This transition promises a new era of innovation.”

To read the full report, visit "The Digital Horizon: Banking’s Shift from Mainframe to AI-Driven Cloud Infrastructure"

About the research

NTT DATA's survey canvasses a diverse array of banking professionals, from all global banking markets, and provides a 360-degree perspective on the sector's modernisation and journey towards innovation and transformation.

Demographics of Respondents:

  • Global Insights: Leaders from a broad geographic spectrum, including the United States, the United Kingdom, Japan, Germany, Spain, Italy, Mexico, and Brazil.
  • Institutional Scope: A cross-section from multinational banks to local banking institutions.
  • Expertise Range: Perspectives across IT, Operations, Innovation, and Strategy.

About NTT DATA

NTT DATA – a part of NTT Group – is a trusted global innovator of IT and business services headquartered in Tokyo. We help clients transform through consulting, industry solutions, business process services, IT modernisation and managed services. NTT DATA enables clients, as well as society, to move confidently into the digital future. We are committed to our clients’ long-term success and combine global reach with local client attention to serve them in over 50 countries. Visit us at nttdata.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240208750914/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye